

Acute Myocardial Infarction and Friedreich's Ataxia

Arvind K. Sharma MBBS, Miki Kiyokawa MD, Edward T. Kim MD, MPH, David T. Lee DO, FACC, and Richard Kasuya MD

Abstract

While cardiac disease is noted in 90% of patients with Friedreich's ataxia (FRDA), the finding of coronary artery disease is unusual. To the best of our knowledge only two cases of acute myocardial infarction (AMI) has been reported in patients with FRDA. Large vessel CAD has not been reported previously in patients with FRDA. We report a young patient with AMI and obstruction of large epicardial arteries.

Introduction

Friedreich's ataxia (FRDA) is an autosomal recessive neuromuscular disorder characterized by spinocerebellar ataxia, loss of tendon reflexes and skeletal deformities. Its association with heart disease has been known since Friedreich's first description in 1863 and is now believed to be present in 90% of patients.^{1,3} The most common cardiac pathology is left ventricular hypertrophy.

Coronary artery disease (CAD) is distinctly unusual with autopsy studies demonstrating only small vessel abnormalities. The functional significance of these have been challenged.³ To the best of our knowledge only two cases of acute myocardial infarction (AMI) have been reported in patients with FRDA,^{4,5} though few reports have alluded to suspected cases.^{2,5,6} Large vessel CAD has not been reported previously in patients with FRDA. We report a young patient with AMI and obstruction of large epicardial arteries.

Case Report

A 35-year-old Caucasian male with FRDA presented for evaluation of chest pain. In childhood he was noted to be slow and clumsy in motor activities such as running and throwing. At age nine, he had bilateral pes cavus corrected surgically. As a teenager, he fell frequently and had difficulty ambulating. He has been wheelchair-bound since age 20. Over the past year, increased upper extremity weakness and incoordination has been noted. Genetic testing had confirmed him to be homozygous for FRDA.

Over the last two years, he experienced intermittent, retrosternal chest pain which was exacerbated markedly eight months prior to evaluation. He then presented to the emergency room with abrupt onset of severe, crushing retrosternal chest pain with radiation to left arm. This was associated with acute onset of dyspnea and diaphoresis. He did not have diabetes mellitus or hypertension and denied use of alcohol or smoking. Family history for premature coronary artery disease was negative. The most recent lipid profile was as follows: total cholesterol 156 mg/dl, triglyceride 238 mg/dl, HDL 26 mg/dl, and LDL 82 mg/dl. Homocysteine level was 19 μ mol/L.

On physical examination, the patient was noted to be a well-developed, dysarthric caucasian male in no acute distress. Vital signs revealed blood pressure of 120/60, heart rate of 100, respiratory rate 18 and he was afebrile. Cardiovascular examination revealed normal heart sounds, a non-displaced PMI and no murmurs

Figure 1.— The right anterior oblique view of the left coronary artery angiogram showing a diffusely narrowed left anterior descending artery (black arrows) without focal abnormality and a small diagonal branch with a 60% proximal lesion. Circumflex artery had a 60% segmental occlusion and a large obtuse marginal branch (culprit vessel) with 90% proximal stenosis (white arrow).



Correspondence to:
Arvind Sharma MD
Washington Hospital Center
Division of Cardiology
110 Irving St NW
Washington DC 20010
E-mail arvshar@aol.com
Phone (202) 877-7597
Fax (202) 877-2247

or features of heart failure. Musculoskeletal examination was significant for pes cavus, hammer toes, and feet inversion. He was areflexic and had loss of proprioception and vibration sensation in lower extremities. He had dysmetria with poor coordination bilaterally and Grade 2/5 lower extremity muscle strength with bilateral extensor plantar response.

EKG changes were consistent with acute infero-lateral MI and the cardiac injury markers confirmed this. His peak troponin I was 46 ng/ml ($n < 2.0$). Echocardiogram done urgently showed apical and inferior hypokinesis and left ventricular hypertrophy (LVH) with wall thickness of 1.8 cm. Cardiac catheterization revealed a diffusely narrowed left anterior descending artery (LAD) without focal abnormality. The diagonal branch was small with a 60% proximal lesion. Circumflex artery had a 60% segmental stenosis and the large obtuse marginal branch with 90% proximal stenosis was believed to be the culprit vessel. A 40% stenosis of the distal right coronary artery was noted. Left ventriculogram showed severe hypokinesis of left ventricular apex and an ejection fraction of 40%. Percutaneous transluminal coronary angioplasty with stent placement of the obtuse marginal vessel was done successfully with TIMI grade III flow. Patient was placed on clopidogrel, aspirin, and metoprolol.

A month later, he was re-admitted for an acute non-Q wave MI with a peak troponin I of 47 ng/ml. Subsequent cardiac catheterization revealed acute occlusion of the stented vessel and the ejection fraction was 35%. Coronary artery bypass was then performed successfully using saphenous vein grafts to the two obtuse marginal branches sequentially, and to the diagonal branch of LAD. During the subsequent month, he developed recurrent chest pain with several hospitalizations necessitating a cardiac catheterization, which revealed complete occlusion of the obtuse marginal graft and 60% occlusion of the graft to the diagonal branch of LAD.

Stress thallium scan showed a large non-reversible perfusion defect involving the lateral, inferior wall and apex of the left ventricle. He was managed conservatively with aspirin, warfarin, metoprolol, quinapril, atorvastatin, folic acid and multivitamins.

Discussion

Cardiac involvement is noted in 90%¹⁻³ of patients with FRDA and has been studied extensively using EKG,^{7,8} cardiac catheterization,⁹ echocardiography,¹⁰⁻¹² radionuclide studies,¹³ and autopsy series.^{2,3,5,14}

The main feature of heart disease associated with FRDA is concentric LVH,¹⁰⁻¹² but asymmetrical septal hypertrophy and left ventricular outflow tract obstruction⁹ may also occur. In some cases, cardiac features precede neurological manifestation.¹⁵⁻¹⁷ Symptoms such as chest pain, palpitations and dizziness occur in the minority of patients. However, in Hewer's series 12% had angina and 73% had cardiac symptoms before death.⁵ They often have arrhythmias, syncope and sudden death. For these reasons, coronary disease has been suspected for many years. However, most reviews and reports on this subject dismiss the coronary lesion as not functionally significant, largely on the basis of Hewer's interpretation.³ He found that only 9% of the 900 arteries had a reduction in the luminal diameter by 50% and concluded that it was not responsible for the extensive muscle fibrosis that was observed. Rather, he believed these coronary lesions to be a secondary phenomena. The narrowing of coronary arteries is, however, not described in other muscular

dystrophy with myocardial involvement and has not been observed in myocardial fibrosis of other etiology.² Though he reports on 27 cases, histological specimens were available in only 16 cases. Only three complete hearts were available to him and 100 sections each of 30um could not have examined the entire 100mm coronary artery. It is possible that the incomplete histopathologic study of the coronary arteries described in these studies may have obscured this finding from the investigator.

James et al. demonstrated small coronary artery occlusions caused by focal fibromuscular dysplasia, intimal proliferation, medial degeneration and fibrosis.¹⁸ Positive acid-Schiff deposits are noted in the subintima and resemble amyloid. However, specific staining for amyloid, fat and fibrin has been consistently negative. Involvement of large coronary artery has been noted in few cases.¹⁸⁻²⁰ Nadas et al. went on to suggest that CAD might be responsible for myocardial damage in FRDA. A thallium stress imaging reported by Casazza et al. demonstrated perfusion defects in three of the thirteen asymptomatic FRDA patients with LVH.²¹ Angiographic studies were limited by the use of non-selective coronary catheterization. Since the inception of selective coronary artery angiography in 1958,²² no explicit reference has been made to coronary vessels in FRDA patients.

In Hewer's study of 82 fatal cases of FRDA, four patients were clinically diagnosed with MI, of these one had a confirmed diagnosis at autopsy. Calvo et al. reported a case of AMI involving microvascular disease and spasm of coronary arteries.⁴ No other confirmed cases of MI in FRDA have since been reported. Our patient had an acute myocardial infarction and left ventricular hypertrophy. On coronary angiography the culprit lesion was determined to be a proximal stenosis of a large epicardial vessel. In view of the above deliberations we believe that the finding of acute myocardial infarction and large vessel coronary artery disease in our patient raises the possibility of cause and effect, however his lipid abnormality and hyperhomocysteinemia could be alternate explanations.

The pathogenetic mechanisms leading to myocardial infarction in our patient may be multifactorial. Multiple case reports^{3,5,6,15,23} make reference to thrombus formation in the heart chambers. In Hewer's autopsy series, twelve out of twenty seven patients showed thrombus formation, of which four cases presented with thrombosis in the heart and in a major artery including the left middle cerebral and the superior mesenteric artery.⁵ Our patient showed thrombosis of stent and later occlusion of the grafts. Thrombosis may have been the primary cause of the cardiac lesion in this patient, and certainly played a significant role once the endothelium was disrupted by these procedures. Vasospasm was reported as one of the mechanisms causing angina.⁷ However, the role of this process in our patient is difficult to determine. His lipid abnormality and hyperhomocysteinemia could be added explanations as noted in the general population at large. There are no reports of homocysteine abnormalities in patients with FRDA. Diabetes mellitus is noted in 10-23% of the FRDA patient,^{1,5} but was not present in our case.

Left ventricular hypertrophy is prevalent in FRDA patient and may have a direct or an indirect impact on mortality. LVH is independently associated with increased incidence of cardiovascular disease and cardiovascular mortality.²⁴ Diminished coronary vasodilator reserve, increased myocardial oxygen demand, subendocardial ischemia, lethal arrhythmias, and diminished ventricular

performance may explain the increased risk associated with left ventricular hypertrophy.²⁵ In a meta-analysis of 39 randomized double blind clinical trials performed through June 1995, the use of angiotensin-converting enzyme inhibitors, calcium-channel blockers, diuretics, or b-blockers was associated with respective reductions in left ventricular mass of 13%, 9%, 7%, and 6%.²⁶ This prominent effect of ACE inhibitors on left ventricular hypertrophy regression may reflect their action on local renin-angiotensin system in addition to the effective blood pressure control. This theory is further supported by the evidence that angiotensin II exerts direct trophic effect on myocardial cells.²⁷ Although the use of these agents and their impact in FRDA patients is not specifically reported, it is likely to be beneficial.

Recent advances have improved the understanding of FRDA at a molecular and genetic level. Chamberlain et al. localized the gene for FRDA to chromosome 9q13 in 1988.²⁸ In 1996, Campuzano et al. discovered the FRDA gene, which is an intronic GAA triplet repeat expansion.²⁹ This led to an accurate genetic testing for this disease. Researchers showed that frataxin, the protein encoded by FRDA gene,³⁰ is an iron transporter protein in mitochondria.³¹ Babcock et al. found that the shortage of this protein in yeast cells led to a toxic build up of iron in the mitochondria. When excess iron reacted with oxygen, free radicals were produced leading to cell destruction.³¹ This syndrome of ataxia and neuropathy, in association with diabetes, cardiomyopathy, deafness and optic atrophy, has all the hallmarks of a mitochondrial disease. Hence, FRDA may very well turn out to be the commonest mitochondrial disease.¹ Further investigation in this area may result in the development of an effective treatment for this condition.

Currently, there is no cure for FRDA, and cardiac disease remains the primary cause of death.^{5,7,15} Median survival is 35 years.⁵ Our patient, 35 years of age, presented with AMI involving large epicardial vessels. To our knowledge, this has been demonstrated for the first time angiographically in a patient with FRDA. Improved awareness and early intervention may significantly affect the outcome. With recent advances in diagnosis and possibly treatment of FRDA, we anticipate a larger number of patients to live longer. The impact of premature coronary artery disease may become more relevant; thus, it may be appropriate to evaluate for coronary artery disease in these patients. In addition, the role of left ventricular hypertrophy and thrombosis in these patients needs to be studied further.

Authors

Department of Medicine, John A. Burns School of Medicine, University of Hawaii

Acknowledgements

We are grateful to Mr. Gary Belcher for his assistance in photography.

References

1. Wood NW. Diagnosing Friedreich's ataxia. Arch Dis Child 1998;78(3): 204-207.
2. Iivemark B, Thoren C. The Pathology of the Heart in Friedreich's Ataxia. Acta Medica Scandinavica 1964;175(2):227-237.
3. Hewer R. The Heart in Friedreich's ataxia. British Heart J 1969;31(5):5-14.

Continued on p. 212

Join us now as a Physician Provider in
a new concept for healthcare delivery!

DirectCare
HAWAII MEDICAL PLAN™



is the answer to providing
quality care and treatment
at an affordable price
with instant savings—

WITH PATIENT'S PAYMENT DIRECT
TO YOU AT TIME OF SERVICE!



No insurance claims! No delayed payments! No adjusted fees!

There's no catch: the patient pays by cash, check or credit card, and receives a 25% discount on office visits and procedures, **based on your usual and customary charges.**

As a Participating Provider, you will benefit by referrals from our member data base, as well as **offering an alternative** to those without insurance, "gap-group" retirees and small business owners.

We will launch in late September, covering a full range of medical and prescription drug services. Primary

care physicians as well as specialists enrolled as DirectCare providers will be immediately available to meet the anticipated demand from individuals, families and non-covered employee dependents.

Some of your current medical insurance patients may have family members who qualify for DirectCare, and if you wish, we can supply you with additional brochures to distribute within your office.

Call 528-2500 to join with us now to begin to affect change!

As a DirectCare provider, you determine what is medically necessary for your patients and concentrate on the delivery of quality health care rather than on reimbursement issues.

DirectCare
HAWAII MEDICAL PLAN™

900 Fort Street Mall, Suite 1280
Honolulu HI 96813
Phone: 808-528-2500 • Fax: 808-545-7696
E-mail: medical@directcarehawaii.com

Call Don Dawson, plan administrator,
at 528-2500
for more information
and to have an application
sent to your office.

Please see the patient brochure which has been inserted in this issue of the Hawaii Medical Journal.

TRIAZ
(benzoyl peroxide)

Rx Only

DESCRIPTION: TRIAZ[®] (benzoyl peroxide) 9% Gel and TRIAZ[®] (benzoyl peroxide) 9% Cleanser are topical, gel-based, benzoyl peroxide containing preparations for use in the treatment of acne vulgaris. Benzoyl peroxide is an oxidizing agent that possesses antibacterial properties and is classified as a keratolytic. Benzoyl peroxide (C₁₄H₁₀O₂) is represented by the following chemical structure:



TRIAZ 9% Gel contains Benzoyl Peroxide 9% as the active ingredient in a gel-based formulation consisting of: Purified Water USP, C12-15 Alkyl Benzoate, Glycerin USP, Cetyl Stearyl Alcohol, Glycolic Acid, Polyacrylamide (and) C13-14 Isoparaffin (and) Laureth-7, Glyceryl Stearate (and) PEG-100 Stearate, Steareth S-2, Sodium Hydroxide, Steareth S-20, Dimethicone 200, Zinc Lactate, Disodium EDTA.

TRIAZ 9% Cleanser contains Benzoyl Peroxide 9% as the active ingredient in a vehicle consisting of: Glycerin USP, White Petrolatum USP, C12-15 Alkyl Benzoate, Sodium Cocoyl Isethionate, Purified Water USP, Special Petrolatum Fraction, Sodium C14-16 Olefin Sulfonate, Zinc Lactate, Carbomer, Potassium Polyphosphate NF, Titanium Dioxide USP, Triethanolamine NF, Glycolic Acid, Lavender Extract, Menthol Crystals USP.

CLINICAL PHARMACOLOGY: The mechanism of action of benzoyl peroxide is not totally understood but its antibacterial activity against *Propionibacterium acnes* is thought to be a major mode of action. In addition, patients treated with benzoyl peroxide show a reduction in lipids and free fatty acids, and mild desquamation (drying and peeling activity) with simultaneous reduction in comedones and acne lesions. Little is known about the percutaneous penetration, metabolism, and excretion of benzoyl peroxide, although it has been shown that benzoyl peroxide absorbed by the skin is metabolized to benzoic acid and then excreted as benzoate in the urine. There is no evidence of systemic toxicity caused by benzoyl peroxide in humans.

INDICATIONS AND USAGE: TRIAZ 9% Gel and TRIAZ 9% Cleanser are indicated for the topical treatment of acne vulgaris.

CONTRAINDICATIONS: These preparations are contraindicated in patients with a history of hypersensitivity to any of their components.

WARNINGS: When using this product, avoid unnecessary sun exposure and use a sunscreen.

PRECAUTIONS: General: For external use only. If severe irritation develops, discontinue use and institute appropriate therapy. After reaction clears, treatment may often be resumed with less frequent application. These preparations should not be used in or near the eyes or on mucous membranes.

Information for Patients: Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. Contact with any colored material (including hair and fabric) may result in bleaching or discoloration. If excessive irritation develops, discontinue use and consult your physician.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Data from several studies employing a strain of mice that are highly susceptible to developing cancer suggest that benzoyl peroxide acts as a tumor promoter. The clinical significance of these findings to humans is unknown. Benzoyl peroxide has not been found to be mutagenic (Ames Test) and there are no published data indicating it impairs fertility.

Pregnancy: Teratogenic Effects: Pregnancy Category C: Animal reproduction studies have not been conducted with benzoyl peroxide. It is not known whether benzoyl peroxide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzoyl peroxide should be used by a pregnant woman only if clearly needed. There are no available data on the effect of benzoyl peroxide on the later growth, development and functional maturation of the unborn child.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when benzoyl peroxide is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy.

OVERDOSAGE: If excessive scaling, erythema or edema occurs, the use of these preparations should be discontinued. To hasten resolution of the adverse effects, cool compresses may be used. After symptoms and signs subside, a reduced dosage schedule may be cautiously tried if the reaction is judged to be due to excessive use and not allergenicity.

DOSE AND ADMINISTRATION: TRIAZ 9% Gel: Apply once or twice daily to cover affected areas, or as directed by your dermatologist. Use after washing with a mild cleanser, such as one of the TRIAZ Cleansers, and water.

TRIAZ 9% Cleanser: Wash affected areas once or twice daily, or as directed by your dermatologist. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10-20 seconds working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or using less often.

HOW SUPPLIED: TRIAZ 9% Gel - 1.5 oz. (42.5 g) tube, NDC 99207-207-01. **TRIAZ 9% Cleanser** - 6 oz. (170.3 g) tube, NDC 99207-208-12. **TRIAZ 9% Cleanser** - 12 oz. (340.2 g) bottle, NDC 99207-208-09.

Store at 15° - 25°C (59° - 77°F).

Covered by US Patents: 5,648,389; 5,254,334; 5,409,706; and 5,632,996.

Manufactured for: MEDICIS, The Dermatology Company[®], Scottsdale, AZ 85258

by: Contract Pharmaceuticals Limited, Mississauga, Ontario L5N 6L6 CANADA

Made in Canada

Prescribing Information as of January 2002

20809-088



"Acute Myocardial...", Continued from p. 201

4. Calvo Iglesias FE, Permanyer MG, Blanco CJ, Rodes CJ, Anivarro BI, Soler SJ. Acute myocardial infarct and Friedrich's disease. *Rev Esp Cardiol* 1995;48 (2): 145-7.
5. Hewer RL. Study of Fatal Cases of Friedrich's Ataxia. *Brit Med* 1968;3:649-52.
6. Kongrad E, Joos HA. Friedrich's Ataxia in Childhood. *Chest* 1972;61(7):644-8.
7. Sohi GS, Drake C, Flowers NC. Friedrich's ataxia associated with Hypertrophic Cardiomyopathy and Coronary Vasospasm. *Clinical Cardiology* 1985;8:537-41.
8. Salih M, Ahlsten G, Staiberg E, Schmidt R, Sunnegardh J, Michaelsson M, Gamstorp I. Friedrich's Ataxia in 13 Children: Presentation and evolution With Neurophysiologic, Electrocardiographic, and echocardiographic Features. *J of Child Neurology* 1990;5:321-326.
9. Cote M, Davignon A, Elias G, Solignac A, Geoffroy G, Lemieux B, Barbeau A. Hemodynamic Findings in Friedrich's Ataxia. *Le Journal Canadien Des Sciences Neurologiques* 1976;3(4):333-336.
10. Morvan D, Komajda M, Doan LD, Brice A, Isnard R, Seck A, Lechat PH, Agid Y, Grosgeat Y. Cardiomyopathy in Friedrich's ataxia: a Doppler-echocardiographic study. *European Heart J* 1992;13: 1393-8.
11. Gunal N, Saraclar M, Oztuku S, Senocak F, Topaloglu H, Karaaslan S. Heart disease in Friedrich's ataxia: A clinical and echocardiographic study. *Acta Paediatrica Japonica* 1996;38: 308-11.
12. Alboliras ET, Shub C, Gomez MR, Edwards WD, Hagler DJ, Reeder GS, Seward JB, Tajik AJ. Spectrum of Cardiac Involvement in Friedrich's Ataxia: Clinical, Electrocardiographic Observations. *Am J Cardiol* 1986;58:518-24.
13. Theriault L, Lamoureux G, Cote M, Poudre G, Lemieux B. The Cardiomyopathy in Friedrich's Ataxia: Isotopic Ventriculography and Myocardial Imaging with Thallium-201. *The Can J of Neurological Sciences* 1984;11:588-591.
14. Unverferth D, Schmidt W, Baker P, Wooley C. Morphologic and Functional Characteristics of the Heart in Friedrich's Ataxia. *The American J of Med* 1987;82:5-10.
15. Tsao CY, Lo WD, Craenen J. Congestive heart failure and cardiac thrombus as first presentations of Friedrich's ataxia. *Pediatr Neurol* 1992;8:313-4.
16. Sanchez PF, Domenech MS, Soler MT. Chest pain during exercise as first manifestation of Friedrich's ataxia: Br Heart J 1995;74:464-7.
17. Sharratt GP, Jacob JB, Hobeika C. Friedrich's Ataxia Presenting as Cardiac Disease. *Pediatric Cardiology* 1985;6:41-2.
18. James TN, Cobbs BW, Coglan HC, McCoy WC, Fisch C. Coronary disease, cardiomyopathy, and conduction system abnormalities in the cardiomyopathy of Friedrich's ataxia. *Brit Heart J* 1987;57:446-57.
19. Russell DS. Myocarditis in Friedrich's ataxia. *J Pathol Bacteriol* 1946;58:739-48.
20. Nadas AS, Alimurung MM, Sieracki LA. Cardiac Manifestations of Friedrich's ataxia. *N Engl J Med* 1951;224:239-44.
21. Casazza F, Palagi B, Picozzi R, Mopurgo M. Myocardial perfusion in Friedrich's ataxia: assessment by dipyridamole thallium-201 imaging. *Cardiologia* 1991;36:213-6.
22. Sones FM, Shirey EK. Cine Coronary Arteriography. *Mod Concepts Cardiovasc Dis* 1962;31:735-8.
23. Reynen K, Claus D, Bornemann A. Large left ventricular thrombus in a patient with Friedrich's ataxia. *Heart* 1996;75(1):82.
24. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med* 1990;322:1561-6.
25. Devereaux RB. Regression of left ventricular hypertrophy. How and why? [Editorial] *JAMA* 1996;275:1517-8.
26. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. *JAMA* 1996;275:1507-13.
27. Harrap SB, Dominiczak AF, Fraser R, Lever AF, Morton JJ, Foy CJ, Watt GCM. Plasma angiotensin II, Predisposition to hypertension, and left ventricular size in healthy young adults: *Circulation* 1996;93:1148-54.
28. Chamberlain S, Shaw J, Rowland A, Wallis J, South S, Nakamura Y, Gabain AV, Farrall M, Williamson R. Mapping of Mutation causing Friedrich's ataxia to human chromosome 9. *Nature* 1988;334:248-49.
29. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcani F, Monoros E, Rodius F, Duclou F, Montecelli A, Zara F, Canizares J, Koutnikova H, Bidichandi SI, Gellera C, Brice A, Trouillas P, DeMichele G, Filla A, De Frutos R, Palau F, Patel PI, DiDonato S, Mandel JL, Coccenza S, Koenig M, Pandolfo M. Friedrich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion. *Science* 1996;271:1423-27. 24-35.
30. Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, Mandel JL, Brice A, Keonig M. Clinical and Genetic Abnormalities in Patients with Friedrich's Ataxia. *N Engl J Med* 1996;335: 1169-75.
31. Babcock M, de Silva D, Oaks R, Kaplan S, Jiralerspong S, Montermini L, Pandolfo M, Kaplan J. Regulation of Mitochondrial Iron Accumulation by Yfh1p, a Putative Homolog of Frataxin. *Science* 1997;276:1709-12.

**Hawaii
Poison
Center**

**Children
Act Fast
So Do
POISONS!**



941-4411

Neighbor Islands Toll Free

1-800-362-3585 More than 40 years of service • Donate to help us save lives